News & Updates

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

High-intensity focused ultrasound (HIFU) appears to be a safe, effective, and minimally invasive treatment option for patients with cirrhotic secondary hypersplenism, a recent study has found.

Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.

In unselected patients with primary sclerosing cholangitis (PSC), yearly surveillance with carbohydrate antigen (CA) 19-9 and magnetic resonance imaging including cholangiopancreatography (MRI/MRCP) does not seem to increase the chances of detecting cancer early, a new study has found.

Magnetic resonance elastography (MRE) plus FIB-4 (MEFIB) outperforms both magnetic resonance imaging [MRI]-aspartate aminotransferase (MAST) and FibroScan-AST (FAST) in detecting stage ≥2 fibrosis and at-risk nonalcoholic steatohepatitis (NASH), reveals a study.